Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Inclusion Criteria: * Advanced IDH mutant hematologic malignancy including: \-- For Dose Escalation Arm C and Dose Expansion Cohort 5: * Patients with newly diagnosed AML who are 75 years or older or have comorbidities that preclude the use of intensive chemotherapy * Patients with R/R AML (US only) * Patients must have received prior therapy * Blasts at least 5% in bone marrow. * Patients must have a qualifying IDH1 R132, IDH2 R140 or IDH2 R172 mutation * Eastern Cooperative Oncology Group (ECOG) 0 to 2 * Adequate organ function * Ability to swallow capsules or tablets * Ability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation * Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following the last dose of study treatment. Exclusion Criteria: * Investigational agent or anticancer therapy within 2 weeks or 5 half-lives, whichever is shorter; or investigational monoclonal antibody within 4 weeks prior to planned start of LY3410738 * For Dose Escalation Arm C and Dose Expansion Cohort 5: * Prior venetoclax treatment is not allowed. * Patients are allowed to receive up to 1 cycle of single agent azacitidine or azacitidine plus venetoclax while waiting for results of locally obtained molecular profiling, including IDH1/IDH2 mutational status, prior to starting on study. * Major surgery wi…